Analyst Gil Blum from Needham maintained a Buy rating on Celcuity (CELC – Research Report) and keeping the price target at $29.00.
Gil Blum has given his Buy rating due to a combination of factors that highlight Celcuity’s promising future prospects. The company’s focus on the pivotal readout for PIK3CA wild type metastatic breast cancer patients, expected in the second quarter of 2025, is a significant factor. This upcoming readout is anticipated to be positive, based on strong Phase I data for gedatolisib and favorable eligibility criteria for the VIKTORIA-1 trial.
Additionally, the management’s guidance on the timing of pivotal results and the progress of the Phase III VIKTORIA-2 study for gedatolisib in first-line HR+/HER2- metastatic breast cancer further supports the Buy rating. The company’s robust financial position, with $235 million to support operations through 2026, also contributes to the positive outlook. These elements collectively underpin the confidence in Celcuity’s potential and justify the Buy rating.
According to TipRanks, Blum is an analyst with an average return of -14.3% and a 28.26% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Geron, and Cartesian Therapeutics.